P42336 (PK3CA_HUMAN) Homo sapiens (Human)
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform UniProtKBInterProSTRINGInteractive Modelling
1068 aa; Sequence (Fasta) ;
13 identical sequences
It is possible new templates exist for this target since these models were created.
Available Structures
109 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| PI3Ka H1047R co-crystal structure with inhibitor in cryptic pocket near H1047R (compound 12). |
Heteromer P27986; | 99.91 | 1×1LT; 1×YQB; | |||
| Crystal Structure of PI3Kalpha |
Heteromer P27986; | 99.81 | 2×PO4; 1×GOL; | |||
| Crystal Structure of PI3Kalpha in complex with the inhibitor NVP-BYL719 |
Heteromer P27986; | 99.81 | 1×1LT; 1×NA; | |||
| PI3Ka H1047R co-crystal structure with inhibitors in two cryptic pockets (compounds 4 and 5). |
Heteromer P27986; | 99.9 | 1×YO4; 1×YOR; 1×YNZ; | |||
| PI3Ka H1047R co-crystal structure with inhibitor in cryptic pocket near H1047R (compound 4). |
Heteromer P27986; | 99.9 | 1×YO4; 1×YNZ; | |||
| STX-478, a Mutant-Selective, Allosteric Inhibitor bound to H1047R PI3Kalpha |
Heteromer P27986; | 99.9 | 10×EDO; 1×X3N; 1×ZWE; | |||
| Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse … |
Heteromer P27986; | 100.0 | 1×GOL; 1×5XV; | |||
| Crystal structure of human T1061E PI3Kalpha in complex with its regulatory subunit and the inhibito… |
Heteromer P27986; | 99.9 | 1×MWF; 3×EDO; 1×PGE; 1×CL; | |||
| p110alpha/p85alpha with compound 5 |
Heteromer P23727; | 100.0 | 1×5H2; | |||
| Co-crystal Structures of the Lipid Kinase PI3K alpha with Pan and Isoform Selective Inhibitors |
Heteromer P27986; | 100.0 | 1×SCN; 1×1LT; | |||
| Crystal Structure of a novel tetrahydropyrazolo[1,5-a]pyrazine in an engineered PI3K alpha |
Heteromer P27986; | 99.8 | 1×3K6; | |||
| Co-crystal Structure of Lipid Kinase PI3K alpha with a selective phosphatidylinositol-3 kinase alph… |
Heteromer P27986; | 100.0 | 1×4Q2; | |||
| STX-478, a Mutant-Selective, Allosteric Inhibitor bound to PI3Kalpha |
Heteromer P27986; | 100.0 | 1×X3N; 1×ZWE; | |||
| Crystal structure of p110alpha H1047R mutant in complex with niSH2 of p85alpha and the drug wortman… |
Heteromer P27986; | 99.9 | 1×KWT; | |||
| Crystal structure of PI3K alpha with PI3K delta inhibitor |
Heteromer P27986; | 100.0 | 1×6CY; | |||
| PI3Ka H1047R co-crystal structure with inhibitor in cryptic pocket (compound 5). |
Heteromer P27986; | 99.9 | 1×YOR; 1×YNZ; | |||
| Crystal structure of p110alpha H1047R mutant in complex with niSH2 of p85alpha |
Heteromer P27986; | 99.9 | ||||
| The co-structure of (R)-4-(6-(1-(cyclopropylsulfonyl)cyclopropyl)-2-(1H-indol-4-yl)pyrimidin-4-yl)-… |
Heteromer P27986; | 99.41 | 1×8DV; | |||
| Crystal Structure of PI3Kalpha in complex with fragment 23 |
Heteromer P27986; | 100.0 | 1×SOA; | |||
| Structure of p110alpha/niSH2 - vector data collection |
Heteromer P27986; | 100.0 | 2×144; 3×SO4; | |||
| Crystal Structure of PI3Kalpha in complex with fragment 10 |
Heteromer P27986; | 100.0 | 1×71N; | |||
| Crystal Structure of PI3Kalpha in complex with fragments 6 and 24 |
Heteromer P27986; | 100.0 | 2×70W; 2×70V; 1×CL; | |||
| Crystal Structure of PI3Kalpha in complex with fragments 17 and 27 |
Heteromer P27986; | 100.0 | 1×71A; 1×71B; | |||
| Crystal Structure of PI3Kalpha in complex with fragment 22 |
Heteromer P27986; | 100.0 | 1×71F; | |||
| Crystal Structure of PI3Kalpha in complex with fragments 19 and 28 |
Heteromer P27986; | 100.0 | 1×71G; 1×ES3; | |||
| Co-structure Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform complex… |
Heteromer P27986; | 99.59 | 1×ZUO; | |||
| Crystal structure of PI3Kalpha in complex with fragments 7 and 11 |
Heteromer P27986; | 100.0 | 1×EPE; 1×70S; 2×FB1; | |||
| Crystal Structure of PI3Kalpha in complex with fragments 12 and 15 |
Heteromer P27986; | 100.0 | 2×71M; 1×LUZ; | |||
| Crystal Structure of PI3Kalpha in complex with fragment 14 |
Heteromer P27986; | 100.0 | 1×71L; | |||
| Co-structure of Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform and … |
Heteromer P27986; | 99.59 | 1×ZTV; 1×SO4; | |||
| Crystal Structure of p110alpha complexed with niSH2 of p85alpha and PI-103 |
Heteromer P27986; | 100.0 | 1×X6K; 2×SO4; 1×GOL; | |||
| Crystal structure of PI3K complex with an inhibitor |
Heteromer P27986; | 100.0 | 1×84R; 1×P6G; 3×SO4; 2×GOL; | |||
| The co-structure of N,N-dimethyl-4-[(6R)-6-methyl-5-(1H-pyrrolo[2,3- b]pyridin-4-yl)-4,5,6,7-tetrah… |
Heteromer P27986; | 99.41 | 1×3K6; | |||
| The co-structure of 3-amino-6-(4-((1-(dimethylamino)propan-2-yl)sulfonyl)phenyl)-N-phenylpyrazine-2… |
Heteromer P27986; | 99.4 | 1×8DY; | |||
| Crystal Structure of PI3Kalpha in complex with fragments 5 and 21 |
Heteromer P27986; | 100.0 | 1×AX7; 1×CAQ; | |||
| Crystal Structure of PI3Kalpha in complex with fragments 20 and 26 |
Heteromer P27986; | 100.0 | 1×718; 2×CL; 1×SAL; | |||
| Crystal Structure of PI3Kalpha in complex with fragment 13 |
Heteromer P27986; | 100.0 | 1×71J; | |||
| Crystal Structure of PI3Kalpha in complex with fragments 4 and 19 |
Heteromer P27986; | 100.0 | 1×CL; 1×70T; 1×2ZV; | |||
| Crystal Structure of PI3Kalpha in complex with fragment 18 |
Heteromer P27986; | 100.0 | 1×71K; | |||
| PI3K alpha in complex with an inhibitor |
Heteromer P27986; | 100.0 | 1×KVJ; | |||
| Crystal Structure of p110alpha complexed with niSH2 of p85alpha |
Heteromer P27986; | 100.0 | 1×SO4; | |||
| Crystal Structure of PI3Kalpha in complex with fragment 8 |
Heteromer P27986; | 100.0 | 1×URF; | |||
| Crystal Structure of PI3Kalpha in complex with diC4-PIP2 |
Heteromer P27986; | 100.0 | 2×PBU; 1×PO4; | |||
| Human PI3K p85alpha/p110alpha H1047R bound to compound 2 |
Heteromer P27986; | 99.9 | 1×UIW; | |||
| Crystal Structure of PI3Kalpha in complex with fragment 29 |
Heteromer P27986; | 100.0 | 2×BHO; | |||
| PI3Ka H1047R co-crystal structure with inhibitor in cryptic pocket near H1047R (compound 7). |
Heteromer P27986; | 99.9 | 1×YQ2; 1×1LT; | |||
| Crystal structure of PI3K complex with an inhibitor |
Heteromer P27986; | 100.0 | 1×84U; 1×GOL; 1×SO4; | |||
| Crystal structure of PI3K complex with an inhibitor |
Heteromer P27986; | 100.0 | 1×84X; 1×SO4; | |||
| Crystal Structure of PI3Kalpha in complex with fragment 9 |
Heteromer P27986; | 100.0 | 1×HPP; | |||
| Crystal Structure of p110alpha in complex with niSH2 of p85alpha |
Heteromer P27986; | 100.0 | ||||
| Crystal Structure of p110alpha complexed with niSH2 of p85alpha and compound 9d |
Heteromer P27986; | 100.0 | 1×XXK; 2×SO4; 1×GOL; | |||
| Human PI3K p85alpha/p110alpha H1047R bound to compound 3 |
Heteromer P27986; | 99.9 | 1×UJC; | |||
| PI 3-kinase alpha with nanobody 3-142, crosslinked with DSG |
Heteromer P27986; | 100.0 | ||||
| Human PI3K p85alpha/p110alpha bound to RLY-2608 |
Heteromer P27986; | 100.0 | 1×XUZ; | |||
| Human PI3K p85alpha/p110alpha H1047R bound to compound 1 |
Heteromer P27986; | 99.9 | 1×UE9; | |||
| Cryo-EM structure of PI3Kalpha in complex with compound 18 |
Heteromer P27986; | 100.0 | 1×L2V; | |||
| Cryo-EM structure of PI3Kalpha in complex with compound 16 |
Heteromer P27986; | 100.0 | 1×7TZ; | |||
| Cryo-EM structure of PI3Kalpha in complex with compound 17 |
Heteromer P27986; | 100.0 | 1×7U5; | |||
| Cryo-EM Structure of p110alpha in complex with p85alpha |
Heteromer P27986; | 100.0 | ||||
| Structure of a human p110alpha/p85alpha complex |
Heteromer P27986; | 100.0 | ||||
| Human PI3K p85alpha/p110alpha bound to compound 2 |
Heteromer P27986; | 100.0 | 1×UIW; | |||
| Human PI3K p85alpha/p110alpha |
Heteromer P27986; | 100.0 | ||||
| PI 3-kinase alpha with nanobody 3-142 |
Heteromer P27986; | 100.0 | ||||
| p85alpha/p110alpha heterodimer H1047R mutant |
Heteromer P27986; | 99.9 | ||||
| PI 3-kinase alpha with nanobody 3-126 |
Heteromer P27986; | 100.0 | ||||
| Cryo-EM structure of p110alpha in complex with p85alpha inhibited by BYL-719 |
Heteromer P27986; | 100.0 | 1×1LT; | |||
| Cryo-EM structure of cancer-specific PI3Kalpha mutant H1047R in complex with BYL-719 |
Heteromer P27986; | 99.9 | 1×1LT; | |||
| CryoEM structure of human PI3K-alpha (P85/P110-H1047R) with QR-7909 binding at an allosteric site |
Heteromer P27986; | 99.9 | 1×UEX; | |||
| CryoEM structure of PI3Kalpha |
Heteromer P27986; | 100.0 | ||||
| PI 3-kinase alpha with nanobody 3-159 |
Heteromer P27986; | 100.0 | ||||
| CryoEM structure of human PI3K-alpha (P85/P110-H1047R) with QR-8557 binding at an allosteric site |
Heteromer P27986; | 99.9 | 1×UJ3; | |||
| Crystal structure of HLA-A*03:01 in complex with a wild-type PIK3CA peptide analogue (Trp-6 Bta) |
Heteromer P04439; P61769; | 100 | 2×GOL; | |||
| Crystal structure of HLA-A*03:01 in complex with a mutant PIK3CA peptide |
Heteromer P04439; P61769; | 88.89 | 5×GOL; 3×FMT; | |||
| Crystal structure of HLA-A*03:01 in complex with a mutant PIK3CA peptide analogue (Trp-6 Bta) |
Heteromer P04439; P61769; | 88.89 | 1×GOL; | |||
| Crystal structure of HLA-A*03:01 in complex with a wild-type PIK3CA peptide |
Heteromer P04439; P61769; | 100 | 2×GOL; | |||
| Crystal structure of human 0606T1-2 TCR bound to HLA-A*03:01 in complex with a mutant PIK3CA peptide |
Heteromer P04439; P61769; | 88.89 | 13×GOL; | |||
| Crystal structure of HLA-A*03:01 in complex with a mutant PIK3CA peptide |
Heteromer P04439; P61769; | 88.89 | 4×FMT; 1×GOL; | |||
| Crystal structure of human 21LT2-2 TCR bound to HLA-A*03:01 in complex with a mutant PIK3CA peptide |
Heteromer P04439; P61769; | 88.89 | 1×ACT; 1×GOL; | |||
| Pi3K alpha lipid kinase with Active Site Inhibitor | monomer | 100.0 | 3×4EL; | |||
| HUMAN PI3KDELTA IN COMPLEX WITH COMPOUND 2F | monomer | 100.0 | 1×VBS; | |||
| Crystal structure of PI3K-alpha in complex with taselisib | monomer | 100.0 | 1×799; | |||
| Human PI3Kalpha in complex with Compound 2-10 ((3S)-3-benzyl-3-methyl-5-[5-(2-methylpyrimidin-5-yl)… | monomer | 100.0 | 1×P5J; 2×GOL; | |||
| p110alpha with GDC-0326 | monomer | 100.0 | 1×5H5; 1×EDO; | |||
| Crystal structure of PI3K-alpha in complex with compound 19 | monomer | 100.0 | 1×X3W; | |||
| Crystal structure of PI3K-alpha in complex with compound 32 | monomer | 100.0 | 1×X3N; | |||
| Crystal structure of PI3K alpha in complex with 3-(2-Amino-benzooxazol-5-yl)-1-isopropyl-1H-pyrazol… | monomer | 100.0 | 1×FE5; | |||
| Crystal structure of PI3K-alpha in complex with compound 30 | monomer | 100.0 | 1×X3R; | |||
| Crystal structure of PI3K alpha in complex with 3-(2-Amino-benzooxazol-5-yl)-4-chloro-1-isopropyl-1… | monomer | 100.0 | 1×FDH; | |||
| Crystal structure of PI3K alpha in complex with 3-(2-Amino-benzooxazol-5-yl)-1-isopropyl-1H-pyrazol… | monomer | 100.0 | 1×FDW; | |||
| Crystal structure of PI3K alpha in complex with 3-(2-Amino-benzooxazol-5-yl)-1-isopropyl-4-methyl-1… | monomer | 100.0 | 1×FCZ; | |||
| CRYSTAL STRUCTURE OF PI3K ALPHA IN COMPLEX WITH A 7-(3-(PIPERAZIN-1-YL)PHENYL)PYRROLO[2,1-F][1,2,4]… | monomer | 100.0 | 1×85S; | |||
| Cryo-EM structure of cancer-specific PI3Kalpha mutant E545K in complex with BYL-719 | monomer | 99.88 | 1×1LT; | |||
| Cryo-EM structure of cancer-specific PI3Kalpha mutant E542K in complex with BYL-719 | monomer | 99.88 | 1×1LT; | |||
| Crystal structure of the p110alpha catalytic subunit from homo sapiens in complex with activator 19… | monomer | 99.89 | 1×QIH; | |||
| Crystal structure of the apo p110alpha catalytic subunit from homo sapiens | monomer | 100.0 | ||||
| Isolated p110a subunit of PI3Ka provides a platform for structure-based drug design | monomer | 100.0 | ||||
| Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kalp… | monomer | 100.0 | 1×KKR; | |||
| Isolated p110a subunit of PI3Ka provides a platform for structure-based drug design | monomer | 100.0 | 1×ML9; | |||
| Crystal structure of human PI3Ka (p110a subunit) with MMV085400 bound to the active site determined… | monomer | 100.0 | 1×ZHY; | |||
| PQR530 [(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-… | monomer | 100.0 | 1×M1J; | |||
| Crystal structure of PI3Kalpha selective Inhibitor PF-06843195 | monomer | 100.0 | 1×VXY; | |||
| Structure of p110 alpha bound to (S)-1-(4-((2-(4-(4-(2-amino-4-(difluoromethyl)pyrimidin-5-yl)-6-(3… | monomer | 100.0 | 1×RNX; | |||
| Structure of PIK3CA with covalent inhibitor 19 | monomer | 100.0 | 1×2Q7; | |||
| Structure of PIK3CA with covalent inhibitor 22 | monomer | 100.0 | 1×2IX; | |||
| Crystal structure of PI3Kalpha inhibitor 10-5429 | monomer | 100.0 | 1×VY1; | |||
| Crystal structure of PI3Kalpha selective Inhibitor 11-1575 | monomer | 100.0 | 1×VY4; | |||
| Crystal structure of PI3Kalpha inhibitor 4-0686 | monomer | 100.0 | 1×VYP; | |||
| Solution structure of the C2 domain from human PI3-kinase p110 subunit alpha | monomer | 100 | ||||
| Crystal structure of PI3K-alpha Ras Binding Domain (RBD) | monomer | 100.0 | ||||
2 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 4l2y.1.A | monomer | 0.85 | 1×XXK; | 100.00 | ||
| 5sxf.1.A | monomer | 0.84 | 100.00 | |||